Fig. 3: Survival estimates in the study cohorts assessed using either CD3 and CD8 immunohistochemistry (IHC) or CD3, CD4 and CD8 IHC. | British Journal of Cancer

Fig. 3: Survival estimates in the study cohorts assessed using either CD3 and CD8 immunohistochemistry (IHC) or CD3, CD4 and CD8 IHC.

From: Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia

Fig. 3

Kaplan–Meier plots demonstrating univariate survival for immune subgroups defined by assessment of either CD3 and CD8 IHC or CD3, CD4 and CD8 IHC (a–h). Forest plot showing adjusted hazard ratios (95% CI) and corresponding P values for multivariable analysis of immune subgroups defined by assessment of either CD3 and CD8 IHC or CD3, CD4 and CD8 IHC; multivariable analysis was adjusted for age, sex, MSI status, stage and treatment in each cohort (i). The pooled analyses for immune subgroups defined by assessment of either CD3 and CD8 IHC or CD3, CD4 and CD8 IHC are stratified by cohort in the multivariable model. Differences in Kaplan–Meier survival curves are presented as log-rank P value. Expression cut-offs were optimised in the Epi700 CRC cohort and applied throughout; CD3 = 300, CD4 = 100, CD8 = 350 positive cells per mm2. Only patients with combined low expression for either CD3 and CD8 IHC or CD3, CD4 and CD8 IHC were considered to have low expression of these biomarkers.

Back to article page